FranciscoHernandez-IlizaliturriMD
Oncology • Buffalo, NYHematologic Oncology
Director of the Lymphoma Research, Head of the Lymphoma Translational Research Program, Professor of Medical Oncology, Department of Medicine, Roswell Park Cancer Institute. Associate Professor of Medicine, SUNY Buffalo School of Medicine and Biomedical Sciences
Dr. Hernandez-Ilizaliturri is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Elm And Carlton St
Buffalo, NY 14263Phone+1 716-845-2300Fax+1 716-845-3894- Is this information wrong?
Education & Training
University at BuffaloFellowship, Hematology and Medical Oncology, 1999 - 2002- University at BuffaloResidency, Internal Medicine, 1996 - 1999
Escuela de Medicina Ignacio A. SantosClass of 1995
Certifications & Licensure
NY State Medical License 2003 - 2024
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma Start of enrollment: 2011 Dec 06
- Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma Start of enrollment: 2007 Apr 17
- Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Start of enrollment: 2013 Aug 27
- Join now to see all
Publications & Presentations
PubMed
- Plain language summary of the TRANSFORM study primary analysis results: lisocabtagene maraleucel as a second treatment regimen for large B-cell lymphoma following fail...Jeremy S Abramson, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernande...> ;Future Oncology. 2024 Mar 28
- Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.Gerson, J., Handorf, E., Villa, D., Gerrie, A., Chapani, P., Li, S., Medeiros, L., Wang, M., Cohen, J., Churnetski, M., Hill, B., Sawalha, Y., Hernandez-Ilizaliturri, ...> ;Blood Advances. 2023 Dec 26
- Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North Am...Barr, P. M., Barr, P. M., Julie M Vose, Kai Fu, Lu Wang, Adnan Mansoor, Douglas Stewart, Hongxia Cheng, Lynette Smith, Ji Yuan, Hina Naushad Qureishi, Brian K Link, Me...> ;Journal of Hematology & Oncology. 2023 Dec 16
- Join now to see all
Abstracts/Posters
- Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) _ Response and Clinical Outcomes in Ultra-Refractory MCLFrancisco J. Hernandez-Ilizaliturri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Utility of Bone Marrow Biopsy in the Staging of T-Cell Lymphoma in the PET-CT EraFrancisco J. Hernandez-Ilizaliturri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Early Complete Remission By Functional Imaging and Intensified Frontline Therapy Are Associated with an Improved Clinical Outcome in Patients with Newly Diagnosed T-Ce...Francisco J. Hernandez-Ilizaliturri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- High Mir-17-92 Expression Is Associated with in Vitro chemoresistance in Burkitt Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Efficacy of Systemic Therapies for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL): A Systematic Literature Review (SLR)Clinically Relevant Abstract2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
Castle Connolly Names 38 Roswell Park Physicians to ‘Top Doctors’ ListFebruary 2nd, 2023- Roswell Park Oncology Experts Named to Castle Connolly ‘Top Doctors’ ListAugust 4th, 2022
- Roswell Park Hematologists Present New Research on FLT3 Inhibitors, CART-19 at ASH Annual MeetingDecember 11th, 2021
- Join now to see all
Professional Memberships
- Member
- Member
- Member
Other Languages
- Spanish
Hospital Affiliations
Roswell Park Comprehensive Cancer CenterBuffalo, New York
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
